被忽视的热带疾病治疗市场：依适应症、药物类型、通路、最终用户、给药途径和治疗方法划分－全球预测，2025-2032年

预计到 2032 年，被忽视的热带疾病治疗市场将成长至 107.9 亿美元，复合年增长率为 6.73%。

关键市场统计数据
基准年 2024	64亿美元
预计年份：2025年	68.3亿美元
预测年份 2032	107.9亿美元
复合年增长率 (%)	6.73%

被忽视的热带疾病治疗优先事项、治疗实施挑战以及实现可持续成果的综合公共卫生干预措施的必要性策略框架

被忽视的热带疾病是许多中低收入国家面临的重大公共卫生挑战，需要协调一致的临床、后勤和政策应对措施。近年来，环境变化、人口迁移和卫生系统能力的提升共同导致了治疗性介入的优先事项和实施方式转变。因此，包括公共卫生机构、非政府组织、临床医护人员和製药企业在内的相关人员必须调整其策略，以维持治疗效果、扩大治疗覆盖范围并维护社区信任。

本分析将核心临床介入置于更广泛的医疗服务和监管背景下，介绍了当前的治疗格局。它强调了整合推广的必要性，这些策略将大规模药物整合策略方法与标靶治疗相结合，并认识到基层医疗机构、社区健康网络和移动外展服务在弥合医疗服务获取差距方面发挥的作用。为此，本导言为后续章节奠定了基础，这些章节将探讨制度变革、政策阻力、针对特定细分领域的见解，并为致力于将循证实践转化为实际影响的领导者提供切实可行的建议。

科学进步、流行病学变化和采购模式演变如何重新定义被忽视的热带疾病治疗模式和供应链韧性

由于科学创新、人口压力和政策环境的变化，被忽视的热带疾病治疗模式正在发生显着变化。诊断灵敏度和就地检验的进步正在缩小临床发现与及时治疗之间的差距，从而支持在传统大规模药物管理宣传活动之外，更精准地使用标靶治疗。同时，药物开发平臺也不断多元化，包括优化的驱虫方案、联合治疗以及可在资源匮乏地区使用的、剂量方案简化的抗生素再利用方案。

同时，更广泛的系统动态正在重塑专案设计。都市化和气候变迁正在改变病媒生物的栖息地和疾病传播模式，促使干预区域和季节性计画进行调整。公共采购和供应链韧性正成为关注焦点，相关人员正投资于缓衝库存、分散式仓库和数位化库存系统，以减少配送延误。最后，公共卫生机构、非政府组织和私人製造商之间的伙伴关係正在不断扩大，从而催生了联合资金筹措模式和集中采购机制，提高了采购效率和营运扩充性。

2025 年美国关税调整重塑了各个治疗类别的供应链、筹资策略和库存计划，从而对营运和采购产生了累积影响。

2025年关税和贸易政策的调整对被忽视的热带病防治项目所用基本药物的采购动态和供应链结构产生了重大影响。原料药和製剂组分关税的增加推高了某些药物类别的到岸成本，促使采购负责人重新评估供应商组合，并在可能的情况下优先考虑本地生产。这促使供应链管理人员加快寻找替代供应商、实现物流路线多元化并加强区域合约的步伐，以应对未来的政策变化。

除了直接的成本影响外，关税带来的干扰也影响了专案进度和库存计划。依赖多层国际供应链的组织由于交货週期延长和合规要求提高，不得不加快订购速度，并加强海关、监管机构和分销合作伙伴之间的协调。此外，前置作业时间的影响加剧了现有活性成分和最终产品法规的复杂性，凸显了统一文件和与国家主管机关积极协调的必要性。因此，专案团队越来越多地将贸易政策情境规划纳入年度采购週期，并考虑采用能够更清晰地在买卖双方之间分配风险的合约条款。

需要采用以细分市场主导的临床和采购方法，透过协调适应症需求、治疗层级、通路和给药方式来优化专案支付。

要深入了解市场，需要根据适应症、产品类别、给药管道、最终用户环境、给药途径和治疗方法进行细分，这些因素都会影响临床决策和营运设计。以登革热、淋巴丝虫病、盘尾丝虫病、血吸虫病和沙眼等疾病为例，各项目的优先事项差异显着。登革热的因应措施着重于病媒控制和快速临床治疗，而淋巴丝虫病和盘尾丝虫病的应对措施则着重于大规模药物管理和发病率控制。沙眼防治计画也将抗生素分发与脸部卫生和环境措施结合。

产品层面的细分同样影响采购和临床路径。驱虫药，包括广泛使用的阿苯达唑、伊维菌素和甲苯达唑等，仍是蠕虫病控制的基石，需要配製成适合大规模给药的製剂。抗节肢动物药和杀虫剂是病媒控制策略的基础，通常与药品一起采购，以提供综合干预方案。抗生素，例如阿奇霉素和多西环素，在沙眼和某些细菌感染后遗症中发挥不同的作用，影响给药方案和安全性监测。抗原生动物药，例如葡甲胺、喷他脒和舒拉明，则针对更专业的适应症，通常需要计画支持以进行肠外给药和不利事件监测。

通路也影响药物取得的动态：政府专案和非政府组织的分销平台是大规模宣传活动的主要管道，医院药房是复杂病例的转诊点，零售药房则为日常护理和后续治疗提供本地途径。相应地，最终用户涵盖了从提供第一线预防措施的诊所和社区健康中心到管理重症或病情迅速进展病例的医院和流动医疗站。给药途径——口服、注射和外用——与服务提供能力相互作用，口服药物通常优先用于扩大覆盖范围，注射药物用于重症病例，外用药物则用于辅助治疗。

另一方面，标靶治疗使临床医生能够根据诊断结果和个别风险状况来制定个人化治疗方案。结合这些细分视角，可以提供多方面的观点，从而有助于针对不同活动环境进行有针对性的采购、优化临床路径和客製化监测框架。

美洲、欧洲、中东和非洲以及亚太地区的区域运作实际情况和流行病学差异将决定适应性治疗策略和供应选择。

区域背景对美洲、中东和非洲以及亚太地区的计画优先事项、监管策略和伙伴关係模式有显着影响，因为每个地区的流行病学模式和运作限制各不相同。在美洲，都市化趋势和卫生系统能力的不平衡导致其工作重点既包括应对虫媒病毒疫情，也包括可持续的社区蠕虫感染疾病控制。该地区的计画实施者强调与基层医疗卫生基础设施的整合，并经常利用市政卫生网路来扩大推广。

在欧洲、中东和非洲，各项专案因应措施面临不同的法规环境和参差不齐的物流基础建设。将大规模药物管理（MDA）宣传活动与宣传活动和跨境协调在部分地区尤其重要，因为在这些地区，流离失所和衝突会改变病毒传播动态，并使供应连续性变得复杂。在亚太地区，郊区人口密度高，加上气候变迁对病媒生态的影响，促使人们采取季节性干预措施和以学校为基础的分发模式。此外，当地生产能力的提高和区域采购联盟的建立，使得供应方案更具韧性，而数位健康工具则为社区层面的监测和依从性监测提供了支持。这些区域差异凸显了根据当地实际情况调整临床通讯协定、分发机制和伙伴关係策略的重要性。

製造商、供应商和服务供应商如何透过配方创新、在地化生产和增强分销能力来重新定义竞争优势

产业相关人员和公共部门合作伙伴正在适应新的产业格局，在这个格局中，临床疗效、监管状态和物流能力决定着竞争地位。专注于驱虫药和抗生素的製药商正在投资研发便捷的给药方法和儿童适用片剂，以方便高剂量给药并提高患者的用药依从性。同时，灭虫剂和杀虫剂供应商则优先考虑安全性和环境保护，并使其配方与全面的病媒控制方案相契合。随着相关人员寻求减少对庞大国际供应链的依赖，并更灵活地应对本地需求波动，契约製造和本地生产设施的重要性日益凸显。

服务供应商，包括物流公司和非政府组织执行机构，凭藉其专业知识脱颖而出，例如肠外疗法的低温运输管理、行动推广能力以及可即时监测宣传活动绩效的数位追踪系统。监管咨询机构和品质保证合作伙伴在加快产品註册和确保符合国家及地方标准方面发挥着至关重要的作用。这些相关人员共同建构了一个生态系统，因此，在充满挑战的营运环境中，协作、透明的合约签订以及对能力建设的投资对于保持专案势头和扩大服务覆盖范围至关重要。

领导者可采取切实可行的策略性倡议，以增强专案韧性、加速服务普及，并使采购和临床策略与当地营运实际情况相符。

产业领导者和公共卫生管理者可以透过将策略投资与营运实际情况和临床优先事项结合来提高效率。首先，应优先考虑能够简化给药方式并提高社区接受度的配方和给药方式创新。其次，应加强区域供应商网路并投资于本地製造伙伴关係关係，以降低贸易政策风险并缩短前置作业时间。

第三，将诊断和监测数据纳入采购和宣传活动规划，以便在临床适宜的情况下，将标靶治疗与大规模给药结合。第四，透过采用数位化库存和追踪解决方案，提高供应链透明度，从而实现库存的主动重新分配和瓶颈的准确预测。最后，深化跨部门合作，将公共机构、非政府执行机构、临床服务提供者和私人生产者聚集在一起，协调资金筹措、培训和社区参与。这些措施共同为领导者提供了一条切实可行的蓝图，以提高计画韧性并加快应对被忽视的热带疾病的进展。

一种透明的方法论，整合了临床文献、实施评估、监管分析和相关人员访谈，以真实世界证据为基础得出操作性结论。

本文的研究结果综合了来自同侪审查的临床文献、专案实施报告、监管公告以及与采购负责人、临床医生和供应链专家相关人员的访谈等多方面证据。数据综合优先考虑了近期关于治疗有效性和安全性的同行评审研究、大规模药物管理宣传活动实施情况的评估以及贸易和采购政策的记录变化。来自第一线实施人员和生产合作伙伴的定性意见为营运可行性和供应链动态评估提供了依据，为技术研究结果提供了实际背景。

此分析方法结合了定性资料的主题综合分析和不同司法管辖区监管及采购惯例的比较研究。在适用情况下，采用临床证据与营运经验相结合的三角验证方法，以得出关于干预措施适用性和分发策略的结论。调查方法强调资讯来源选择的透明度、对证据品质的严格评估以及反覆的同行检验，以确保解释基于当前的实践和监管限制。

概述了为持续推进被忽视的热带病防治工作而製定的策略重点，强调整合、本地能力建构和数据主导的专案设计。

总之，被忽视的热带疾病治疗领域正处于曲折点，临床进展、供应链现代化和适应性政策应对必须协同作用，才能维持进展。有效的计画应将大规模药物管理与有针对性的临床干预相结合，并辅以增强的本地生产能力、改进的诊断方法以及能够提高供应链应对力的数位化工具。此外，注重製剂创新和以社区为中心的用药管理对于扩大覆盖范围、同时确保安全性和可接受性至关重要。

展望未来，相关人员应优先考虑跨部门合作、投资本地能力建构以及将监控资料纳入专案设计。这样做将使计画实施者和生产者能够更好地预测可能出现的干扰因素，优化资源利用，并以公平和永续的方式提供治疗。这些共同努力对于在未来几年保持对抗被忽视的热带疾病的势头至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩大公私合营，加速被忽视的热带疾病药物研发
• 将基于智慧型手机的快速诊断测试整合到血吸虫病社区控制项目中
• 采用mRNA疫苗平台，为地方性流行区内臟利什曼原虫症提供一种新型免疫策略。
• 实施数位化供应链管理解决方案，以优化被忽视的热带疾病治疗药物的「最后一公里」配送。
• 慈善捐款和影响力投资资金激增，用于治疗皮肤利什曼原虫症的联合治疗
• 加速监管核准新型大环内酯製剂，以应对盘尾丝虫病抗药性挑战
• 引入人工智慧驱动的预测模型，以增强被忽视的热带疾病药物研发流程中的标靶识别。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 被忽视的热带疾病治疗市场（依适应症划分）

• 登革热
• 淋巴丝虫病
• 盘尾丝虫病
• 血吸虫病
• 沙眼

9. 被忽视的热带疾病治疗市场（依药物类型划分）

• 驱虫药
  • 阿苯达唑
  • 伊维菌素
  • 甲苯咪唑
• 抗节肢动物药物
• 抗生素
  • 阿奇霉素
  • 多西环素
• 抗原生动物
  • 葡甲胺
  • 喷他脒
  • 猛击
• 杀虫剂

第十章 被忽视的热带疾病治疗市场（依通路划分）

• 政府项目
• 医院药房
• 非政府组织分发
• 零售药房

第十一章 被忽视的热带疾病治疗市场（以最终用户划分）

• 诊所
• 社区健康中心
• 医院
• 移动营地

12. 被忽视的热带疾病治疗市场（依给药途径划分）

• 口服
• 肠外
• 外用

13. 被忽视的热带疾病治疗市场（依治疗方法划分）

• 大规模药物管理
• 标靶治疗

第十四章 各地区被忽视的热带疾病治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 被忽视的热带疾病治疗市场（以群体划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国被忽视的热带疾病治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Johnson & Johnson
  • Novartis AG
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.

The Neglected Tropical Disease Treatment Market is projected to grow by USD 10.79 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 6.40 billion
Estimated Year [2025]	USD 6.83 billion
Forecast Year [2032]	USD 10.79 billion
CAGR (%)	6.73%

A strategic framing of neglected tropical disease treatment priorities, delivery challenges, and the imperative for integrated public health interventions that drive sustained outcomes

Neglected tropical diseases remain a defining public health challenge in many low- and middle-income settings, demanding coordinated clinical, logistical, and policy responses. In recent years, the confluence of environmental change, population movements, and evolving health system capacities has reshaped how treatment interventions are prioritized and delivered. Consequently, stakeholders across public health agencies, non-governmental organizations, clinical providers, and pharmaceutical manufacturers must align their approaches to preserve treatment efficacy, extend reach, and sustain community trust.

This analysis introduces the current treatment landscape by situating core clinical interventions within broader delivery and regulatory contexts. It emphasizes the need for integrated strategies that bridge mass drug administration approaches with targeted therapies, while recognizing the role of primary care sites, community health networks, and mobile outreach in closing access gaps. To that end, the introduction sets the stage for subsequent chapters that examine systemic shifts, policy headwinds, segmentation-specific insights, and practical recommendations for leaders seeking to translate evidence into impact.

How scientific advances, shifting epidemiology, and evolving procurement models are redefining treatment paradigms and supply chain resilience for neglected tropical diseases

The treatment landscape for neglected tropical diseases is undergoing transformative shifts driven by scientific innovation, demographic pressures, and changing policy environments. Advances in diagnostic sensitivity and point-of-care testing are narrowing the gap between clinical detection and timely treatment, which in turn supports more precise use of targeted therapies alongside traditional mass drug administration campaigns. At the same time, drug development pipelines have diversified to include optimized anthelmintic regimens, combination therapies, and repurposed antibiotics that can be deployed in resource-limited settings with simplified administration protocols.

Simultaneously, broader systemic dynamics are reshaping program design. Urbanization and climate variability alter vector habitats and disease transmission patterns, prompting a recalibration of intervention zones and seasonality planning. Public procurement and supply chain resilience have become focal areas, with stakeholders investing in buffer stocks, decentralized warehousing, and digital inventory systems to reduce distribution lag. Finally, partnerships between public health authorities, non-governmental organizations, and private manufacturers are expanding, enabling collaborative financing models and pooled procurement mechanisms that enhance procurement efficiency and operational scalability.

Cumulative operational and procurement consequences stemming from United States tariff adjustments in 2025 that reshaped supply chains, sourcing strategies, and inventory planning across therapeutic categories

The introduction of tariffs and trade policy changes in 2025 materially influenced procurement dynamics and supply chain configurations for essential therapeutics used in neglected tropical disease programs. Increased tariff burdens on active pharmaceutical ingredients and formulation components amplified landed costs for some drug families, prompting procurement officers to reassess supplier portfolios and prioritize localized manufacturing where feasible. In response, supply chain managers accelerated efforts to qualify alternative suppliers, diversify logistics routes, and strengthen in-region contracting to buffer against future policy volatility.

Beyond direct cost effects, tariff-induced disruption had downstream implications for program timing and inventory planning. Organizations reliant on multi-stage international supply chains encountered longer lead times and heightened compliance requirements, which required earlier ordering windows and expanded coordination across customs, regulatory, and distribution partners. Moreover, tariff impacts intersected with existing regulatory complexity for active ingredients and finished products, intensifying the need for harmonized documentation and advance engagement with national authorities. As a consequence, program teams are increasingly embedding trade-policy scenario planning into annual procurement cycles and exploring contractual terms that allocate risk more explicitly between buyers and suppliers.

Segment-driven clinical and procurement imperatives that reconcile indication-specific needs, therapeutic classes, distribution pathways, and administration modes to optimize program delivery

A nuanced understanding of the market requires segmentation by indication, product class, delivery channel, end-user setting, route of administration, and treatment approach, each of which informs clinical decision-making and operational design. When examining disease indications such as dengue, lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, program priorities differ markedly: vector control and rapid clinical management dominate dengue responses, whereas mass drug administration and morbidity management are central to lymphatic filariasis and onchocerciasis control efforts. Schistosomiasis interventions emphasize school- and community-based chemotherapy, and trachoma programs integrate antibiotic distribution with facial cleanliness and environmental measures.

Product-level segmentation similarly shapes procurement and clinical pathways. Anthelmintics, including widely used agents such as albendazole, ivermectin, and mebendazole, remain foundational for helminth control and require formulations suitable for mass administration. Antiarthropodals and insecticides underpin vector control strategies and are procured alongside pharmaceutical products to achieve integrated intervention packages. Antibiotics such as azithromycin and doxycycline have distinct roles in trachoma and certain bacterial sequelae, influencing dosing regimens and safety monitoring. Antiprotozoals, including meglumine, pentamidine, and suramin, cater to more specialized indications and often necessitate programmatic support for parenteral administration and adverse event surveillance.

Distribution channels also determine access dynamics. Government programs and NGO distribution platforms are primary conduits for large-scale campaigns, hospital pharmacies serve as referral hubs for complex cases, and retail pharmacies offer local access for routine care and follow-up. Correspondingly, end users vary from clinics and community health centers that deliver first-line preventive measures to hospitals and mobile camps that manage severe or rapidly evolving cases. Routes of administration-oral, parenteral, and topical-interact with service delivery capacity, with oral regimens generally preferred for scale, parenteral routes reserved for severe disease, and topical formulations supporting adjunctive care.

Finally, treatment approach differentiates program design: mass drug administration is effective for community-level burden reduction and elimination objectives, while targeted therapy allows clinicians to tailor regimens according to diagnostic confirmation and individual risk profiles. Taken together, these segmentation lenses provide a multidimensional perspective that facilitates targeted procurement, optimized clinical pathways, and tailored monitoring frameworks for diverse operational contexts.

Regional operational realities and epidemiological nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adaptive treatment strategies and supply choices

Regional context significantly influences program priorities, regulatory navigation, and partnership models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct epidemiological patterns and operational constraints. In the Americas, urbanization trends and heterogeneous health system capacities shape a dual focus on outbreak responsiveness for arboviral threats and sustained community-based control for helminth infections. Program implementers in this region often emphasize integration with primary healthcare platforms and leverage municipal health networks to extend outreach.

Across Europe, the Middle East & Africa, program responses contend with diverse regulatory environments and variable logistics infrastructure; integration of MDA campaigns with routine maternal and child health services has emerged as a pragmatic approach to broaden coverage in resource-limited settings. Humanitarian operations and cross-border coordination are particularly salient in parts of this region where displacement and conflict alter transmission dynamics and complicate supply continuity. In the Asia-Pacific, high population density in peri-urban zones, coupled with climatic influences on vector ecology, drives seasonally targeted interventions and school-based delivery models. Additionally, growing local manufacturing capacity and regional procurement consortia are enabling more resilient supply options, while digital health tools support community-level surveillance and adherence monitoring. These regional distinctions underline the importance of tailoring clinical protocols, distribution mechanisms, and partnership strategies to local realities.

How manufacturers, suppliers, and service providers are redefining competitive advantage through formulation innovation, localized production, and enhanced distribution capabilities

Industry participants and public-sector partners are adapting to a landscape where clinical efficacy, regulatory agility, and logistical competence determine competitive positioning. Pharmaceutical manufacturers focused on anthelmintics and antibiotics are investing in simplified dosing formulations and pediatric-friendly tablets to facilitate mass administration and improve adherence. At the same time, suppliers of antiarthropodals and insecticides are aligning formulations with integrated vector management programs, emphasizing safety profiles and environmental stewardship. Contract manufacturers and in-region production facilities are gaining strategic importance as stakeholders seek to reduce dependency on extended international supply chains and respond more nimbly to local demand fluctuations.

Service providers, including logistics firms and NGO implementers, are differentiating through expertise in cold-chain management for parenteral therapies, mobile outreach capabilities, and digital tracking systems that monitor campaign performance in real time. Regulatory consultancies and quality assurance partners play a critical role in accelerating product registration and ensuring compliance with national and regional standards. Collectively, these actors contribute to an ecosystem where collaboration, transparent contracting, and investment in capacity building are essential to sustain program momentum and expand access in challenging operational settings.

Practical strategic moves for leaders to strengthen program resilience, accelerate access, and align procurement and clinical strategies with local operational realities

Industry leaders and public health managers can advance impact by aligning strategic investments with operational realities and clinical priorities. First, prioritize formulation and delivery innovations that simplify administration and increase acceptability in community settings; this reduces reliance on intensive clinical infrastructure and supports higher coverage in mass drug administration contexts. Second, strengthen regional supplier networks and invest in local manufacturing partnerships to mitigate trade-policy risks and shorten lead times, while ensuring quality management systems are in place to maintain product integrity.

Third, integrate diagnostics and surveillance data into procurement and campaign planning so that targeted therapies complement mass administration where clinically appropriate; this will improve resource allocation and reduce unnecessary exposure to pharmacologic agents. Fourth, enhance supply chain transparency by adopting digital inventory and tracking solutions that enable proactive reallocation of stocks and more accurate anticipation of bottlenecks. Finally, deepen cross-sector collaborations that link public agencies, non-governmental implementers, clinical providers, and private manufacturers to coordinate financing, training, and community engagement. Taken together, these steps create a pragmatic roadmap for leaders to improve program resilience and accelerate progress against neglected tropical diseases.

A transparent methodology integrating clinical literature, implementation evaluations, regulatory analysis, and stakeholder interviews to ground operational conclusions in real-world evidence

The findings presented here synthesize multiple lines of evidence drawn from peer-reviewed clinical literature, program implementation reports, regulatory notices, and stakeholder interviews with procurement officers, clinicians, and supply chain specialists. Data synthesis prioritized recent peer-reviewed studies on treatment efficacy and safety, implementation evaluations of mass drug administration campaigns, and documented changes in trade and procurement policies. Qualitative inputs from field implementers and manufacturing partners informed assessments of operational feasibility and supply chain dynamics, providing real-world context to technical findings.

Analysis methods combined thematic synthesis for qualitative data with comparative review of regulatory and procurement practices across jurisdictions. Where applicable, triangulation between clinical evidence and operational experience guided conclusions about intervention suitability and distribution strategies. The methodology emphasized transparency in source selection, critical appraisal of evidence quality, and iterative validation with subject-matter experts to ensure that interpretations remain grounded in current practice and regulatory constraints.

Synthesis of strategic priorities that emphasize integration, localized capacity, and data-driven program design to sustain progress against neglected tropical diseases

In conclusion, the treatment landscape for neglected tropical diseases is at an inflection point where clinical advances, supply chain modernization, and adaptive policy responses must converge to sustain progress. Effective programs will blend mass drug administration with targeted clinical interventions, supported by stronger regional manufacturing capabilities, improved diagnostics, and digital tools that enhance supply chain responsiveness. Moreover, an emphasis on formulation innovation and community-centered delivery will be essential to expanding reach while preserving safety and acceptability.

Moving forward, stakeholders should prioritize cross-sector collaboration, investment in localized capacity, and integration of surveillance data into program design. By doing so, implementers and manufacturers can better anticipate disruptions, optimize resource use, and deliver treatments in ways that are both equitable and sustainable. These combined efforts will be critical to maintaining momentum against neglected tropical diseases in the years ahead.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of public-private partnerships for R&D acceleration in neglected tropical disease drug development
• 5.2. Integration of smartphone-enabled rapid diagnostic testing into community control programs for schistosomiasis
• 5.3. Adoption of mRNA vaccine platforms for novel immunization strategies against visceral leishmaniasis in endemic regions
• 5.4. Implementation of digital supply chain management solutions to optimize last-mile distribution of neglected tropical disease treatments
• 5.5. Surge in philanthropic and impact investment funding for combination therapies targeting cutaneous leishmaniasis
• 5.6. Fast-track regulatory approvals for novel macrocyclic lactone formulations addressing onchocerciasis drug resistance challenges
• 5.7. Deployment of AI-driven predictive modeling to enhance target identification in neglected tropical disease drug discovery pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Disease Treatment Market, by Disease Indication

• 8.1. Dengue
• 8.2. Lymphatic Filariasis
• 8.3. Onchocerciasis
• 8.4. Schistosomiasis
• 8.5. Trachoma

9. Neglected Tropical Disease Treatment Market, by Drug Type

• 9.1. Anthelmintics
  • 9.1.1. Albendazole
  • 9.1.2. Ivermectin
  • 9.1.3. Mebendazole
• 9.2. Antiarthropodals
• 9.3. Antibiotics
  • 9.3.1. Azithromycin
  • 9.3.2. Doxycycline
• 9.4. Antiprotozoals
  • 9.4.1. Meglumine
  • 9.4.2. Pentamidine
  • 9.4.3. Suramin
• 9.5. Insecticides

10. Neglected Tropical Disease Treatment Market, by Distribution Channel

• 10.1. Government Programs
• 10.2. Hospital Pharmacy
• 10.3. NGO Distribution
• 10.4. Retail Pharmacy

11. Neglected Tropical Disease Treatment Market, by End User

• 11.1. Clinics
• 11.2. Community Health Centers
• 11.3. Hospitals
• 11.4. Mobile Camps

12. Neglected Tropical Disease Treatment Market, by Route Of Administration

• 12.1. Oral
• 12.2. Parenteral
• 12.3. Topical

13. Neglected Tropical Disease Treatment Market, by Treatment Approach

• 13.1. Mass Drug Administration
• 13.2. Targeted Therapy

14. Neglected Tropical Disease Treatment Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Neglected Tropical Disease Treatment Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Neglected Tropical Disease Treatment Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. GlaxoSmithKline plc
  • 17.3.2. Merck & Co., Inc.
  • 17.3.3. Merck KGaA
  • 17.3.4. Pfizer Inc.
  • 17.3.5. Sanofi S.A.
  • 17.3.6. Johnson & Johnson
  • 17.3.7. Novartis AG
  • 17.3.8. Bayer AG
  • 17.3.9. Takeda Pharmaceutical Company Limited
  • 17.3.10. Eisai Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD